Intellia (NTLA) Drops 4.76% on May 5

Intellia Therapeutics Inc (NASDAQ: NTLA) shares are down 4.76%, or $2.65 per share, as on 12:13:08 est today. Since opening the day at $52.62, 480,516 shares of Intellia have traded hands and the stock has ranged between $54.80 and $52.13.  

So far this year the company has a YTD change of 52.89%.

Intellia is set to release earnings on 2022-05-05.

For technical charts, analysis, and more on Intellia visit the company profile.

About Intellia Therapeutics Inc

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

To get more information on Intellia Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Intellia Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Cigna Beats Q1 Revenue and Earnings Estimates, Raises Full Year Guidance
PepGen Goes Public in $108 Million IPO
Bausch + Lomb Raises $630 Million in IPO, Missing Expectations
Aeglea BioTherapeutics Raises $45 Million Via Registered Direct Offering
Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer’s Drug
Decentralization Drives Progress
Stocks To Watch in 5G Wireless Growth Wave: Jeff Kagan
Betting Against Elon Musk Has Not Been Profitable

Read more here: Source link